Category: Investment, Biotech, Biodefense
Medical Device Stock Trading Alert: Aethlon Medical (OTCBB: AEMD) Closes up 11.9% on News
Visit this company: www.aethlonmedical.com
Point Roberts WA - December 4, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV). The compassionate-use program, which has been approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity), will provide individuals who previously failed or subsequently relapsed standard-of-care drug regimens with treatment access to the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dosing, duration and tolerability of drug therapies.
Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors including biotech and medical technology stocks issues a trading alert for Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. The stock closed up Monday 11.9% on over 720,000 shares volume following news of the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV).
Full news: http://www.investorideas.com/CO/AEMD/news/2012/12031.asp
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/ Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/ Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/ today/ investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/ Resources/ Newsletter.asp
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source Investorideas.com 800 665 0411